Analysts Issue Forecasts for Pfizer Inc.’s FY2018 Earnings (PFE)

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Jefferies Group lifted their FY2018 earnings per share (EPS) estimates for shares of Pfizer in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the biopharmaceutical company will earn $2.90 per share for the year, up from their previous forecast of $2.77. Jefferies Group currently has a “Neutral” rating and a $40.00 target price on the stock.

A number of other equities research analysts have also recently commented on PFE. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research note on Monday, January 8th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research note on Wednesday. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target for the company in a research note on Monday, January 8th. Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $38.94.

Pfizer (PFE) traded down $0.21 during trading on Thursday, reaching $36.97. The company’s stock had a trading volume of 10,520,000 shares, compared to its average volume of 16,330,000. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 52 week low of $30.90 and a 52 week high of $37.37. The stock has a market capitalization of $220,370.00, a PE ratio of 22.68, a PEG ratio of 2.45 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period last year, the business posted $0.61 earnings per share. The firm’s revenue was up .9% compared to the same quarter last year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

Pfizer declared that its Board of Directors has authorized a stock repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

In other news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,450 shares of company stock valued at $1,065,220. Company insiders own 0.06% of the company’s stock.

Several large investors have recently made changes to their positions in the company. BKD Wealth Advisors LLC raised its position in Pfizer by 3.4% during the fourth quarter. BKD Wealth Advisors LLC now owns 103,664 shares of the biopharmaceutical company’s stock valued at $3,755,000 after acquiring an additional 3,451 shares in the last quarter. WealthTrust Arizona LLC raised its position in Pfizer by 146.7% during the fourth quarter. WealthTrust Arizona LLC now owns 19,708 shares of the biopharmaceutical company’s stock valued at $714,000 after acquiring an additional 11,720 shares in the last quarter. Community Financial Services Group LLC raised its position in Pfizer by 0.6% during the fourth quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock valued at $7,856,000 after acquiring an additional 1,375 shares in the last quarter. Westpac Banking Corp raised its position in Pfizer by 4.6% during the fourth quarter. Westpac Banking Corp now owns 639,100 shares of the biopharmaceutical company’s stock valued at $23,148,000 after acquiring an additional 28,036 shares in the last quarter. Finally, Cullinan Associates Inc. raised its position in Pfizer by 0.5% during the fourth quarter. Cullinan Associates Inc. now owns 309,116 shares of the biopharmaceutical company’s stock valued at $11,196,000 after acquiring an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 69.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Issue Forecasts for Pfizer Inc.’s FY2018 Earnings (PFE)” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/18/analysts-issue-forecasts-for-pfizer-inc-s-fy2018-earnings-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply